IMTX

SVB Securities analyst Jonathan Chang reiterated a Buy rating on Immatics (IMTX - Research Report) on August 9 and set a price target of $17.00. The company's shares closed yesterday at $11.99.Chang covers the Healthcare sector, focusing on stocks such as ImmunoGen, Replimune Group, and Immatics. According to TipRanks, Chang has an average return of -10.3% and a 30.00% success rate on recommended stocks. Immatics has an analyst consensus of Strong Buy, with a price target consensus of $21.67, an 80.73% upside from current levels. In a report released on August 9, Chardan Capital also reiterated a Buy rating on the stock with a $28.00 price target.
https://www.tipranks.com/news/blurbs/svb-securities-keeps-their-buy-rating-on-immatics-imtx?utm_source=advfn.com&utm_medium=referral